Engineered virus teams up with immune drug to attack tough liver tumors
NCT ID NCT07411781
Summary
This early-stage study is testing the safety and initial effectiveness of a new two-part treatment for advanced colorectal cancer that has spread to the liver and hasn't responded to standard therapies. About 25-30 patients will receive injections of a genetically engineered virus directly into their liver tumors, combined with an intravenous immunotherapy drug. The main goal is to see if this combination is safe and can trigger the patient's own immune system to fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.